Dr. Jaime Ghitelman, M.D.
What this data tells you about Dr. Ghitelman
Dr. Jaime Ghitelman is a cardiovascular disease in South Miami, FL, with 17 years in practice. Based on federal Medicare data, Dr. Ghitelman performed 3,420 Medicare services across 1,602 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ghitelman received a total of $30,991 from 47 pharmaceutical and/or device companies across 537 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ghitelman is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Remote patient monitoring management, 20 min/month | 895 | $37 | $105 |
| Remote patient monitoring device, 30 days | 544 | $39 | $110 |
| Office visit, established patient (30-39 min) | 398 | $91 | $270 |
| Office visit, established patient (20-29 min) | 320 | $67 | $195 |
| Electrocardiogram (EKG), 12-lead | 289 | $11 | $30 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 254 | $32 | $91 |
| Regadenoson injection (Lexiscan) for heart stress test | 96 | $46 | $110 |
| New patient office visit (45-59 min) | 77 | $121 | $360 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 66 | $137 | $386 |
| Echocardiogram, transthoracic | 52 | $142 | $424 |
| Telephone medical discussion with physician, 21-30 minutes | 47 | $104 | $220 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 42 | $54 | $150 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 42 | $351 | $500 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 34 | $313 | $792 |
| Ultrasonic guidance for blood vessel access | 29 | $13 | $32 |
| EKG interpretation and report | 29 | $7 | $11 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 27 | $88 | $240 |
| Cardiac catheterization | 25 | $226 | $720 |
| Ultrasound of leg arteries at rest and after exercise | 25 | $119 | $354 |
| Ultrasound of leg arteries or artery grafts | 23 | $190 | $520 |
| Chemical destruction of first incompetent vein of arm or leg using imaging guidance | 21 | $1,396 | $3,650 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 21 | $336 | $960 |
| Ultrasound of both sides of head and neck blood flow | 18 | $100 | $308 |
| Hospital follow-up visit, moderate complexity | 18 | $68 | $158 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 17 | $2,281 | $4,906 |
| Initial hospital admission, moderate complexity | 11 | $112 | $303 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (60%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in cardiovascular disease and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Ghitelman is a clinical cardiology specialist, with moderate Medicare volume, and high industry engagement (speaking/promotional, top 11%), with 17 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Ghitelman experienced with remote patient monitoring management, 20 min/month?
Does Dr. Ghitelman receive payments from pharmaceutical companies?
How do Dr. Ghitelman's costs compare to other cardiovascular diseases in South Miami?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology